From bnnbreaking.com
By Sakchi Khandelwal
The article addresses arthritis, an inflammation of the body’s joints that causes pain, deformity, and difficulty moving. While it typically affects people over the age of 40 and those who are overweight, it can occur at any age. There are various types of arthritis including osteoarthritis, rheumatoid arthritis, gout, lupus, fibromyalgia, and septic arthritis. Osteoarthritis is associated with aging and affects fingers, knees, and hips, while rheumatoid arthritis is an autoimmune disease affecting hands and feet.
Understanding Arthritis
Arthritis is an inflammation of the body’s joints, causing pain, deformity, and difficulty in movement. Symptoms may appear in anyone, with a higher incidence in people over 40 and those who are overweight. There are different types of arthritis, such as osteoarthritis and rheumatoid arthritis, each with different causes. Treatment generally consists of joint rest, alternating application of ice and heat, weight loss, physical exercise, and the use of analgesics. In more severe cases, surgery may be required.
Arthritis Treatment
The treatment for arthritis varies, including rest, application of ice and heat, weight loss, physical exercise, pain relievers, and in some cases, arthroplasty or surgery. It is essential that the treatment is guided by an orthopaedist or rheumatologist and that self-medication is not practiced.
Emerging Therapeutic Approaches
The Institute of Drug Technology (Farmanguinhos/Fiocruz) signed a technology transfer agreement with Pfizer Brasil to produce tofacitinib citrate, a generic clone of Xeljanz®, aiming to expand the population’s access to treatment of immune-mediated inflammatory diseases, such as rheumatoid arthritis. The technology transfer of tofacitinib citrate from Pfizer by Farmanguinhos/Fiocruz will take place in stages, with the registration of the drug’s molecule clone already submitted to Anvisa. The approved drug in Brazil is incorporated into SUS and presents a mechanism that acts within cells, inhibiting janus kinase (JAK), a protein important in the inflammatory processes characteristic of some immune-mediated diseases, inaugurating a class of drugs for rheumatoid arthritis.
No comments:
Post a Comment